NCT02042066

Safety and Efficacy Study of Extracorporeal Shockwave Therapy in the Treatment of Patients With Resistant Hypertension

Efficacy and Safety of Low Intensity- Extracorporeal Shockwave Therapy in Drug Resistant Hypertension

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Medispec · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Low intensity shockwaves have been proven in animal and human studies to increase tissue perfusion, promote angiogenesis and tissue regeneration and improve neural function. The hypothesis of this study is that shockwave therapy could improve the symptoms of patients with resistant hypertension.

Conditions

• Hypertension, Resistant to Conventional Therapy

Interventions

Type	Name	Description
DEVICE	Omnispec model Vascuspec	Energy Density: 0.09 - 0.1 mJ/mm2 Extracorporeal Shockwave Therapy

Timeline

• Start date: 2015-01-01
• Primary completion: 2016-01-01
• First posted: 2014-01-22
• Last updated: 2014-01-22

Locations

1 site across 1 country: Israel